Form 4: Teva Pharmaceutical Executive Mark Sabag Reports Share Transactions
SEC Form 4
Mark Sabag, an Executive Vice President at Teva Pharmaceutical Industries, reported the vesting and disposal of restricted share units and acquisition of additional restricted share units on March 5, 2025.
Summary
- On March 5, 2025, Mark Sabag, an Executive Vice President at Teva Pharmaceutical Industries, reported transactions involving Teva's ordinary shares and restricted share units.
- 23,765 restricted share units vested and were subsequently disposed of, resulting in the acquisition of 23,765 ordinary shares.
- Following these transactions, Sabag directly owns 488,911 ordinary shares.
- Additionally, Sabag acquired 62,893 new restricted share units on the same date.
- These new restricted share units will vest in installments from March 5, 2026, to March 5, 2029.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing share transactions, with no inherent positive or negative sentiment. It's a factual report of transactions.
Future Outlook
The document outlines the vesting schedule for the newly granted restricted share units, indicating future equity-based compensation for the reporting person.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like Teva. It provides transparency into the equity holdings and transactions of key executives.
Comparison to Industry Standards
- Equity compensation is a standard practice in the pharmaceutical industry to align executive interests with shareholder value.
- Companies like Pfizer, Novartis, and Johnson & Johnson also utilize restricted stock units and stock options as part of their executive compensation packages.
- The vesting schedules and amounts of equity grants are generally benchmarked against peer companies to ensure competitiveness in attracting and retaining talent.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership of ordinary shares.
- The vesting of restricted share units is part of the executive compensation plan, impacting employee benefits.
Key Dates
| Date | Description |
|---|---|
| 03/05/2021 | Date restricted share units were granted, vesting in installments. |
| 03/05/2022 | 23,764 restricted share units vested. |
| 03/05/2023 | 23,764 restricted share units vested. |
| 03/05/2024 | 23,764 restricted share units vested. |
| 03/05/2025 | 23,765 restricted share units vested and disposed of; 62,893 new restricted share units granted; reported transaction date. |
| 03/05/2026 | 15,723 restricted share units will vest. |
| 03/05/2027 | 15,723 restricted share units will vest. |
| 03/05/2028 | 15,723 restricted share units will vest. |
| 03/05/2029 | 15,724 restricted share units will vest. |
| 03/07/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.